Apeloa Pharmaceutical Co., Ltd.

Company Profile

Apeloa Pharmaceutical Co., Ltd. was founded in 1989. After more than 30 years of development, the company has established strong capabilities in pharmaceutical research, development, and manufacturing. Headquartered in Hengdian, Zhejiang, the company primarily engages in pharmaceutical industry investment, equity investment management, biopharmaceutical R&D, manufacturing, sales, and import/export. It has production bases in Dongyang (Zhejiang), Weifang (Shandong), Dongzhi (Anhui), and Quzhou (Zhejiang), forming four core business segments: active pharmaceutical ingredients (APIs), contract development and manufacturing organization (CDMO), pharmaceuticals, and medical beauty and cosmetic ingredients. The company holds prominent positions in various industry associations, including serving as Vice President of the China Medical Insurance Import and Export Chamber of Commerce, Vice President of the Zhejiang Pharmaceutical Industry Association, Executive Director of the Zhejiang Pharmaceutical Association, and Council Member of the Shanghai Yangtze River Delta Business Innovation Research Institute. It is also recognized as a national pilot enterprise for "integration of two industries," a leading biopharmaceutical enterprise in Zhejiang Province, and a participant in Zhejiang's "Eagle Action" initiative. In 2023, the company ranked 36th on the Ministry of Industry and Information Technology's Top 100 List, 2nd in API exports, and 20th on the Menet Network's Top 100 Chemical Pharmaceutical Companies List. The API business has accumulated significant technological achievements and talent resources. The company has been a pioneer in China's API industry, continuously investing in environmental protection, technological upgrades, and product development. Its APIs have formed strong competitive advantages in cost, quality, EHS (environment, health, and safety), and technology. Since 2007, its major API production sites have passed official audits by China's NMPA, the U.S. FDA, the EU's EMEA, and Japan's PMDA, establishing it as a leading enterprise in specialty APIs in China. Additionally, the company is advancing continuous, automated, digital, and intelligent pharmaceutical manufacturing, achieving a leap from "manufacturing" to "smart manufacturing." As a core service provider for the global and Chinese innovative drug industry, the CDMO business leverages its strengths in R&D and high-efficiency manufacturing. It has formed long-term strategic partnerships with top innovative pharmaceutical companies worldwide. With robust quality, EHS, and R&D capabilities, it offers efficient, flexible, and high-quality solutions to global partners, covering everything from laboratory-stage drug candidate discovery and synthetic route design to process development, optimization, and validation for clinical-stage candidates, as well as commercial production post-approval. This business has experienced sustained high growth. The pharmaceutical business focuses on scaling its product portfolio and implementing a global strategy. Based on market demand and clinical value, it strengthens R&D in improved new drugs and mid-to-high-end generic drugs. The company has established well-known domestic brands such as "Baishixin" and "Tianliwei," with several products approved for entry into regulated markets in Europe and the U.S. Key generic drug products have achieved rapid growth through integrated API and formulation strategies, volume-based procurement, and the creation of high technical barriers and differentiated strategies. The medical beauty and cosmetic ingredients business builds on the company's CDMO project experience, utilizing synthetic biology platforms, peptide platforms, and chemical synthesis advantages. It is gradually developing product pipelines in areas such as sunscreens, proteins, beauty oligopeptides, and other active ingredients, while expanding into recombinant proteins, botulinum toxin raw materials, and formulations. The company is also building capabilities in cosmetic ingredient formulations and branding. The company implements a development strategy of "refining APIs, strengthening CDMO, excelling in pharmaceuticals, and expanding into medical beauty." Its R&D innovation system fully supports this strategy, with annual R&D investment accounting for over 5% of revenue. It has established an API Technology Center, CDMO R&D Centers (in Hengdian, Shanghai, and Boston), and a Drug Research Institute (in Hangzhou), creating several leading technology and support platforms in China and globally. Currently, the company employs over 1,300 R&D personnel, including specially appointed experts, "Double Dragon Scholars," and Ph.D. holders with extensive overseas experience. It has also formed a Science and Technology Advisory Committee and collaborated with Shanghai Jiao Tong University, Shanghai Institute of Technology, and Zhejiang University of Technology to establish platforms in biology, chemistry, and engineering, empowering technological innovation and intelligent manufacturing. Adhering to the development philosophy of "strong technological R&D, high-standard compliance, and low-cost manufacturing," the company drives high-quality growth through innovation. It is committed to becoming a global leader in technology-driven pharmaceutical manufacturing and contributing to China's goal of becoming a world-class pharmaceutical manufacturing powerhouse. e.